

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

MX-1

RRID:CVCL_4774

Type: Cell Line

Proper Citation

RRID:CVCL_4774

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4774

Proper Citation: RRID:CVCL_4774

Description: Cell line MX-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast carcinoma

Defining Citation: [PMID:10969801](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:29045385](#)

Comments: Characteristics: Established from a tumor xenograft established in athymic mice., Population: Caucasian., Part of: JWGray breast cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MX-1

Synonyms: MX1, MXI

Cross References: BTO:BTO_0004179, CLO:CLO_0009915, EFO:EFO_0006457, ArrayExpress:E-MTAB-2706, BioSample:SAMN03472921, ChEMBL-Cells:ChEMBL3308046, ChEMBL-Targets:ChEMBL613704, CLS:300296, DepMap:ACH-002328, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM844611, GEO:GSM844612, GEO:GSM844613, GEO:GSM845398, GEO:GSM1172893, GEO:GSM1172987, LINCS_HMS:51090, LINCS_LDP:LCL-2072, NCI-DTP:MX-1, PharmacDB:MX1_973_2019, PubChem_Cell_line:CVCL_4774, Wikidata:Q54907134

ID: CVCL_4774

Record Creation Time: 20220427T220828+0000

Record Last Update: 20260904T014713+0000

Ratings and Alerts

No rating or validation information has been found for MX-1.

No alerts have been found for MX-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. Molecular cancer therapeutics, 25(1), 7.

Lau HR, et al. (2025) ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling. Molecular oncology, 19(10), 2833.

Giuntini F, et al. (2025) MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer. Cell reports, 44(12), 116604.

Toader D, et al. (2023) Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. Molecular cancer therapeutics, 22(9), 999.

Oliemuller E, et al. (2020) SOX11 promotes epithelial/mesenchymal hybrid state and alters tropism of invasive breast cancer cells. eLife, 9.